Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 10/2014

01-10-2014 | Research Article

Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists

Authors: C. Camps-Herrero, L. Paz-Ares, M. Codes, R. López-López, A. Antón-Torres, P. Gascón-Vilaplana, V. Guillem-Porta, A. Carrato, J. J. Cruz-Hernández, C. Caballero-Díaz, A. Blasco-Cordellat, J. A. Moreno-Nogueira, E. Díaz-Rubio

Published in: Clinical and Translational Oncology | Issue 10/2014

Login to get access

Abstract

Purpose

The economic situation showed that the resources devoted to health spending are limited, making rationalisation of their consumption necessary. The relevance of pharmacoeconomic analyses is becoming crucial. The ECO Foundation, promoting the quality of oncology care, set out to analyse the consensus on the new therapeutic targets inclusion and the integration of pharmacoeconomics when evaluating their effectiveness.

Methods

Study about pharmacoeconomic estimations was performed during the first ECO-Seminar (2010). It was developed using a modified Delphi method, in four stages: (1) committee coordinator establishment, (2) expert-panel selection, (3) preparation and submission of survey (1 question) by email, and (4) analysis of the degree of consensus reached.

Results

Results were obtained from surveys completed by 35 experts. Regarding the tolerable annual cost for the approval of new drugs, 68.8 % of the respondents considered a cost per quality-adjusted life year (QALY) gained between €30,000 and 100,000 acceptable (34.4 % €30,000–60,000; 34.4 % €60,000–100,000), 21.9 % of the respondents found costs between €100,000–150,000/QALY and 9.3 % of the respondents found costs above €150,000/QALY acceptable.

Conclusions

The costs of new drugs are higher than traditional treatments, making it a priority to identify subgroups of patients with specific molecular profiles as candidates for higher-efficiency-targeted therapies. The allocation of the available resources to the most effective interventions, to achieve the best clinical outcomes with lower costs and best subjective profile possible, allows expenditure to be rationalised. Pharmacoeconomic studies are a basic tool for obtaining better health outcomes according to the available resources, while also considering the other needs of the population.
Appendix
Available only for authorised users
Literature
1.
Darba J. Pharmaceutical expenditure and therapeutic value of new medicines in Spain. Pharmacoeconomics. 2003;21(16):1211–2.PubMedCrossRef
2.
3.
Sargent D. What constitutes reasonable evidence of efficacy and effectiveness to guide oncology treatment decisions? Oncologist. 2009;15:19–23.CrossRef
4.
Ocaña A, Tannock IF. When are “positive” clinical trials in oncology truly positive? J Natl Cancer Inst. 2011;103:16–20.PubMedCrossRef
5.
Sobrero A, Bruzzi P. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. J Clin Oncol. 2009;27:5868–73.PubMedCrossRef
6.
7.
8.
Fojo T, Parkinson DR. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res. 2010;16:5972–80.PubMedCrossRef
9.
Ministerio de Sanidad y Consumo. Estrategia en Cáncer del SNS. 2005.
10.
López Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, et al. Propuesta de guía para la evaluación económica aplicada las tecnologías sanitarias. Gac Sanit. 2010; 24(02):154–70.
11.
Groose SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8:165–78.CrossRef
12.
Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold an what other factors influence its decision? A binary choice analysis. Health Econ. 2004;13:437–52.PubMedCrossRef
13.
Bobinac A, Van Exel NJ, Rutten FF, Brouwer WB. Willingness to pay for a quality-adjusted life-year: the individual perspective. Val Health. 2010;13:1046–55.CrossRef
14.
Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained. What is the threshold of cost-effectiveness? Health Econ. 2010;19:422–37.PubMedCrossRef
15.
Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Health Technol Assess Health Care. 2011;27:71–6.CrossRef
16.
Bobinac A, van Exel NJ, Rutten FF, Brouwer WB. Inquiry into the relationship between equity weights and the value of the QALY. Val Health. 2012; 1119–26.
17.
Donaldson C, Baker R, Mason H, Jones-Lee M, Lancsar E, Wildman J, et al. The social value of a QALY: raising the bar or barring the raise? BMC Health Serv Res. 2011;11:8.PubMedCrossRefPubMedCentral
18.
Pinto-Prades JL, Loomes G, Brey R. Trying to estimate a monetary value for the QALY. J Health Econ. 2009;28:553–62.PubMedCrossRef
19.
Zhao FL, Yue M, Yang H, Wang T, Wu JH, Li SC. Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making? Med Care. 2011;49:267–72.PubMedCrossRef
20.
Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit. 2002;16:334–43.PubMedCrossRef
21.
Prieto L, Sacristán JA, Antoñanzas F, Rubio-Terrés C, Pinto JL, Rovira J. Análisis coste-efectividad en la evaluación económica de intervenciones sanitarias. Med Clin (Barc). 2004;122(13):505–10.CrossRef
22.
Camps C, Caballero C, Sirera R, Blasco A, Cayuela D, Gil M, et al. Can the Spanish care system assume the new costs of medications against cancer? Clin Transl Oncol. 2008;10(2):96–101.PubMedCrossRef
23.
Isla D, González-Rojas N, Nieves D, Brosa M, Finnern HW. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clin Transl Oncol. 2011;13:460–71.PubMedCrossRef
24.
Oyagüez I, Frías C, Seguí MA, Gómez-Barrera M, Casado MA, Queralt Gorgas M. Eficiencia de tratamientos oncológicos para tumores sólidos en España. Farm Hosp. 2013;37:240–59.PubMed
25.
Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium—the just price. J Clin Oncol. 2013;28:3600–4.CrossRef
26.
Tsimberidou AM, Ringborg U, Schilsky RL. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. Am Soc Clin Oncol Educ Book. 2013:118–25. doi:10.​1200/​EdBook_​AM.​2013.​33.​118.
27.
Pfister DG. The just price of cancer drugs and the growing cost of cancer care: oncologists need to be part of the solution. J Clin Oncol. 2013;28:3487–9.CrossRef
28.
Piccart MJ. Why your preferred targeted drugs may become unaffordable. Cancer Res. 2013;73:5849–51.PubMedCrossRef
Metadata
Title
Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists
Authors
C. Camps-Herrero
L. Paz-Ares
M. Codes
R. López-López
A. Antón-Torres
P. Gascón-Vilaplana
V. Guillem-Porta
A. Carrato
J. J. Cruz-Hernández
C. Caballero-Díaz
A. Blasco-Cordellat
J. A. Moreno-Nogueira
E. Díaz-Rubio
Publication date
01-10-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 10/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1170-1

Other articles of this Issue 10/2014

Clinical and Translational Oncology 10/2014 Go to the issue

Research Article

Estrogen combined with progesterone decreases cell proliferation and inhibits the expression of Bcl-2 via microRNA let-7a and miR-34b in ovarian cancer cells

Research Article

Looking for complementary alternatives to CTCAE for skin toxicity in radiotherapy: quantitative determinations

Research Article

Second primary malignancies in patients with neuroendocrine tumors

Brief Research Article

Aldehyde dehydrogenases in early stage lung cancer: nuclear expression

Special Article

TTD consensus document on the diagnosis and management of exocrine pancreatic cancer

Brief Research Article

Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana’s predictive model
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits